11 August 2021>: Clinical Research
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
Jianquan Zhu 1ABCDEF , Yu Zhang 1BC , Meng Wang 1BC , Zhenfa Zhang 1BC , Dongsheng Yue 1BC , Shichang Liu 2BC , Yi Pan 3BC , Changli Wang 1AE*DOI: 10.12659/MSM.930738
Med Sci Monit 2021; 27:e930738
Figure 3 Kaplan-Meier curves of patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin. (A) Progression-free survival in intention-to-treat population. (B) Progression-free survival in patients who underwent surgery. (C) Overall survival in intention-to-treat population. (D) Overall survival in patients who underwent surgery. CI – confidence interval.